News About: R&D
Seegene succeeds in developing reagents using AI for the first time
Seegene succeeded in developing a molecular diagnosis reagent only in 4 days with its self-developed automated AI reagent development system.
Seegene(CEO Jong-Yoon Chun), a molecular diagnosis company, announced on t...
Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment
Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multip...
KPBMA establishes private-public AI Novel Drug Development Support Center by 2019
The ‘Artificial Intelligence(AI) Novel Drug Development Support Center’ jointed established by private and public organizations will be launched in 2019 in Korea, which attract attention of the pharmaceutical industry...
Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug
Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December....
Foreign CROs hot in Korea, accounting for more than 30% of total CROs in Korea
In the Korean clinical study market, foreign CROs(contract research organization) are reportedly getting popular.
According to the ‘Korea Clinical Trail Industry Statistics’ published by the Korea National Enterprise...
Korea follows only 71.4% of U.S. drug development technology
It was analyzed the Korea’s technological level of drug development was 71.4% of what the U.S. had and the technological gap was 4.1 years.
The Ministry of Health and Welfare and the Korea Health Industry Development...
Standigm reveals novel drug discovering services using new AI technology
A novel drug discovering company based on artificial intelligence ‘Standigm(CEO Jin-Han Kim)’ announced the company selected as the next-generation pharmaceutical and biotechnology company at the ‘23th Bio-Europe,’ an...
Phase III clinical trials accounted for the most of total clinical trials in Korea
Since the number of approvals for clinical trial plan was rapidly increasing for the past several years, it is now common to hear ‘clinical trial’ around us.
Thus, the Ministry of Food and Drug Safety(MFDS) analyzed ...
‘Serious’ polarization of R&D investment among innovative pharmaceutical companies
It was criticized polarization of R&D investments was getting intensified among innovative pharmaceutical companies certified to have excellent new drug development and overseas expansion capabilities.
While there is...
225 pipelines of biologics being developed in Korea
There were reportedly 225 cases of clinical trials for biologics being developed in Korea.
According to the Ministry of Food and Drug Safety(MFDS), there were ongoing clinical trials for total 225 products at the end...
Which are outstanding tetravalent vaccines even for the young?
Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer
Who will be the next Pharmaceutical Safety Bureau Director?
Celltrion completes clinical trials for Remsima SC for European approval
Sales listed pharmas made in the first half of the year
March
January
February
March
April
May
June
July
August
September
October
November
December
2025
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
23 | 24 | 25 | 26 | 27 | 28 | 1 |
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 | 31 | 1 | 2 | 3 | 4 | 5 |
00:00
01:00
02:00
03:00
04:00
05:00
06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
